Phesi selected as finalist for 2018 scrip award

Date: 10. 10. 2018

(BUSINESS WIRE) October 10, 2018

EAST LYME, Conn. Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced it is a finalist for a 2018 Scrip Award, one of the pharmaceutical and biotech industries’ most prestigious honors. The company has been selected as one of six finalists in the Best Technological Development in Clinical Trials – Tech Sponsor-focused category, which “recognize[s] the promising and disruptive role that digital health technology now plays in clinical drug development,” according to the Scrip Awards 2018 website.

Read the full press release at Business Wire.

Related news
10. 07. 2021
Phesi Big Data Analysis of Over 200,000 Hepatitis B and C Patients Identifies Typical Patient to Help Drive Forward Disease Elimination Goals Read more
08. 02. 2021
Sensyne grows medical research dataset to 60 million patients Read more
01. 05. 2021
Phesi and Sensyne Health agree collaboration to advance development of synthetic arms in clinical trials Read more
09. 11. 2020
Phesi data show clinical trial suspensions continue to rise as covid-19 impact on development persists Read more
01. 22. 2019
Phesi at the 8th crown congress Read more